WeLeader Biomedical Co

WeLeader Biomedical Co Receivables

The Accounts Receivable of WeLeader Biomedical Co (7713.TWO) as of Oct 25, 2026 is 257.36 M TWD. In the previous year, Accounts Receivable was 251.67 M TWD — a change of 2.26% (higher).

Receivables

257.36 MTWD

YoY

2.26%

Last updated:

Accounts Receivable of WeLeader Biomedical Co is 2024 257.36 M TWD. Accounts Receivable of WeLeader Biomedical Co was 2023 251.67 M TWD. It decreases by 2.26% higher compared to the previous year.

The WeLeader Biomedical Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2020
221.86 M TWD
Jan 1, 2021
269.08 M TWD
Jan 1, 2022
248.03 M TWD
Jan 1, 2023
251.67 M TWD
Jan 1, 2024
257.36 M TWD
The WeLeader Biomedical Co Receivables history
YEARReceivablesYoY
257.36 MTWD+2.26%
251.67 MTWD+1.47%
248.03 MTWD-7.82%
269.08 MTWD+21.28%
221.86 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd generates revenue through the agency and trading of in vitro diagnostic instruments and reagent-related products, primarily serving domestic markets. The company provides distribution, after-sales, and maintenance services for laboratory reagents, consumables, instruments, and equipment, alongside construction planning for medical testing laboratories. Additional services include equipment procurement, operational coaching, human resources training, and digital medical examination platforms. Domestic clients purchase these integrated solutions for healthcare facilities and laboratories. The firm's product portfolio focuses on medical testing-related services, including operational coaching and digital platform solutions, which are sold to healthcare institutions requiring comprehensive laboratory support. Distribution of in vitro diagnostic instruments and reagents forms a core revenue stream, supported by ancillary services like equipment procurement and site construction planning. These offerings target domestic healthcare providers seeking efficient laboratory management solutions. WeLeader Biomedical Co Ltd's business model combines product sales with service delivery, emphasizing domestic market penetration. The company's revenue is derived from both the sale of diagnostic instruments and reagents and the provision of specialized services such as operational coaching and digital platform access. Healthcare institutions and laboratories are the primary buyers of these integrated offerings, leveraging the company's expertise in laboratory construction and equipment maintenance. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WeLeader Biomedical Co stock

Accounts Receivable of WeLeader Biomedical Co is 257.36 M TWD in 2024.

Accounts Receivable of WeLeader Biomedical Co changed from 251.67 M TWD to 257.36 M TWD, representing a 2.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's WeLeader Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — WeLeader Biomedical Co

All Key Metrics — WeLeader Biomedical Co